Andreas Norlin
Chief Tech/Sci/R&D Officer presso ASCELIA PHARMA AB
Patrimonio netto: 10 650 $ in data 31/03/2024
Profilo
Andreas L.
Norlin is the founder of Xkout Bioscience AB.
He is currently the Director at ApoGlyx AB and the Chief Scientific Officer at Ascelia Pharma AB.
Dr. Norlin has a graduate and doctorate degree from the University of Lund.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
ASCELIA PHARMA AB
0.04% | 13/07/2023 | 12 364 ( 0.04% ) | 10 650 $ | 31/03/2024 |
Posizioni attive di Andreas Norlin
| Società | Posizione | Inizio |
|---|---|---|
| ASCELIA PHARMA AB | Chief Tech/Sci/R&D Officer | 01/01/2020 |
ApoGlyx AB
 ApoGlyx AB BiotechnologyHealth Technology ApoGlyx AB engages in research and development of aquaporin inhibitors. It conducts sales of know-how, licenses, and chemical substance in biochemistry. The company was founded by Per Ola Kjellbom on April 22, 2008 and is headquartered in Lund, Sweden. | Director/Board Member | - |
Precedenti posizioni note di Andreas Norlin
| Società | Posizione | Fine |
|---|---|---|
| Xkout Bioscience AB | Founder | - |
Formazione di Andreas Norlin
| University of Lund | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ASCELIA PHARMA AB | Health Technology |
| Aziende private | 2 |
|---|---|
ApoGlyx AB
ApoGlyx AB BiotechnologyHealth Technology ApoGlyx AB engages in research and development of aquaporin inhibitors. It conducts sales of know-how, licenses, and chemical substance in biochemistry. The company was founded by Per Ola Kjellbom on April 22, 2008 and is headquartered in Lund, Sweden. | Health Technology |
| Xkout Bioscience AB |
- Borsa valori
- Insiders
- Andreas Norlin
